Pharmaceutical, Medical Devices, & Life Sciences

Our Approach

Pharmaceutical, medical device and life sciences products are in constant demand.

Litigation presents ongoing risk and quick resolution is critical. Using in-depth analysis, expert medical opinions, reviewing medical literature and applicable law, we develop cost-effective strategies to resolve our cases.

Not only do we help companies assess risk and get the best possible results, we set legal precedent and play an important role in establishing laws that benefit the industry.

We understand the difficulties of shepherding products through clinical trials, regulatory processes and ultimately bringing them to market.

Our unique blend of legal, scientific, technical and market experience includes a wide array of pharmaceutical and medical device products. We’ve resolved numerous spinal implant and latex glove cases without claim payments by our clients.

We’ve also successfully handled many other types of cases, including:

Diabetic drugs
NSAIDs
Blood products
Hip implants
Intraocular lenses
IUDs
Breast implants
Collagen implants

Quick resolutions to disputes are critical to a company’s success and the reputation of its product. We pursue early case disposition whenever possible. If trial is unavoidable, we aggressively defend cases in the courtroom at a national, regional and local level.

Who we work with

Pharmaceutical, medical device and life sciences companies

Media Clips

A Year Out and a Supreme Court Case Still Leaves Patent Questions Unanswered

Intellectual Property & Technology Law Journal | December 05, 2019

Intellectual Property associates Sydney Pritchett, Ben Rosborough and Ravi Braich authored this patent alert about remaining questions and uncertainty following the U.S. Supreme Court ‘s ruling in Helsinn Healthcare S.A. v. Teva Pharmaceuticals U.S.

“Ascertainability” in pharmaceutical and medical device cases

Defense Research Institute | September 04, 2019

Complex Commercial Disputes partner Vivian Quinn and associate Tracey Scarpello, both of the Buffalo office, co-wrote this article in the Defense Research Institute’s publication, analyzing the impact of the ascertainability requirement on pharmaceutical and medical device class actions.

GSK wins access to records on researcher’s link to Zofran plaintiffs’ lawyers

Reuters Legal | July 25, 2019

This story mentions Boston Government Investigations and White Collar Defense partner Mark Seltzer for his representation of GlaxoSmithKline in an ongoing matter regarding the drugmaker’s antinausea medication, Zofran.

GSK gets 2nd chance to argue preemption in Zofran MDL

Law360 | July 10, 2019

The following articles mention Boston Government Investigations and White Collar Defense partners Mark Seltzer and Brian French for their representation of GlaxoSmithKline in an ongoing matter related to the pharmaceutical company’s anti-nausea drug Zofran. One of the issues is whether federal law pre-empts state law in the case.

Judge to seek FDA’s views on Zofran birth defect cases against GSK

Reuters Legal | July 10, 2019

GSK renews Zofran birth defect dismissal bid after Supreme Court ruling

Reuters Legal | June 04, 2019

This article mentions Boston Government Investigations and White Collar Defense partner Mark Seltzer for his representation of GlaxoSmithKline in an ongoing matter related to its anti-nausea medication Zofran.

GSK fights to subpoena publisher of Zofran study by plaintiffs' consultant

Reuters Legal | April 02, 2019

Boston Government Investigations & White Collar Defense partner Mark Seltzer is mentioned in this story for his representation of pharmaceutical company GlaxoSmithKline in an ongoing matter related to the company’s anti-nausea drug Zofran.

GSK accuses Zofran plaintiffs' law firms of funding academic study

Reuters | March 05, 2019

Boston Government Investigations and White Collar Defense partner Mark Seltzer is mentioned in this article for representing GlaxoSmithKline in an ongoing dispute related to the company’s anti-nausea drug Zofran.

FDA never saw birth-defect tests on GSK drug, families say

Law360 | September 12, 2018

Boston Government Investigations & White Collar Defense partners Mark Seltzer and Brian French are mentioned in this article for their ongoing representation of GlaxoSmithKline in a suit regarding their drug Zofran.

Consumer protection – preemption – eyedrops

Massachusetts Lawyers Weekly | August 27, 2018

Litigation Department head Scott O’Connell is mentioned in this case summary for his role as co-counsel for a group of pharmaceutical companies. The companies successfully defended a suit by a class of customers seeking to force changes to the design of the companies’ eyedrops bottles.

1st Circuit says challenge to Rx eyedropper size preempted

Law360 | August 26, 2018

Nixon Peabody is mentioned in this article as co-counsel for a group of pharmaceutical companies who won dismissal of a First Circuit class-action suit regarding the design of their eyedrop bottles.

Attorney cites 1st Circuit in seeking contempt in Biolitec IP case

Law360 | April 25, 2018

Albany commercial litigation partner Bill Reynolds is mentioned in this story for his representation of AngioDynamics Inc. in an ongoing dispute with Biolitec AG.

GSK Zofran users bicker over scope of patient discovery

Law360 | April 24, 2018

Boston government investigations and white collar defense partners Mark Seltzer and Brian French are mentioned in this story for their representation of pharmaceutical company GlaxoSmithKline in a lawsuit brought by users of its anti-nausea medication Zofran.

Show More Show Less

Press